0000315066-16-005776.txt : 20160503 0000315066-16-005776.hdr.sgml : 20160503 20160503145646 ACCESSION NUMBER: 0000315066-16-005776 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20160502 FILED AS OF DATE: 20160503 DATE AS OF CHANGE: 20160503 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Dimension Therapeutics, Inc. CENTRAL INDEX KEY: 0001592288 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 463942159 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 840 MEMORIAL DRIVE STREET 2: 4TH FLOOR CITY: CAMBRIDGE STATE: MA ZIP: 02139 BUSINESS PHONE: 617-401-0011 MAIL ADDRESS: STREET 1: 840 MEMORIAL DRIVE STREET 2: 4TH FLOOR CITY: CAMBRIDGE STATE: MA ZIP: 02139 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: FMR LLC CENTRAL INDEX KEY: 0000315066 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-37601 FILM NUMBER: 161615038 BUSINESS ADDRESS: STREET 1: 245 SUMMER STREET CITY: BOSTON STATE: MA ZIP: 02210 BUSINESS PHONE: 6175706339 MAIL ADDRESS: STREET 1: 245 SUMMER STREET CITY: BOSTON STATE: MA ZIP: 02210 FORMER NAME: FORMER CONFORMED NAME: FMR CORP DATE OF NAME CHANGE: 19920717 4 1 primary_doc.xml PRIMARY DOCUMENT X0306 4 2016-05-02 0 0001592288 Dimension Therapeutics, Inc. DMTX 0000315066 FMR LLC 245 SUMMER STREET BOSTON MA 02210 0 0 1 1 See Remark 1 Common Stock 2016-05-02 4 J 0 2106784 0 D 4893322 I See Footnote 1 F-Prime Capital Partners Healthcare Fund III LP made a pro-rata distribution to its partners, without payment of consideration, of 5,950,090 shares of Dimension Therapeutics Inc. previously reported by FMR LLC. F-Prime Capital Partners Healthcare Fund III LP distributed 3,838,249 shares to Impresa Fund III Limited Partnership, 44,862 shares to F-Prime Capital Partners Healthcare Advisors Fund III LP (FPCPHA) and 2,066,979 shares to a recipient whose shares are not subject to reporting by the undersigned (an Other Recipient). FPCPHA made a pro-rata distribution to its partners, without payment of consideration, of 5,057 shares to F-Prime Inc, a wholly-owned subsidiary of FMR LLC, and 39,805 shares to Other Recipients. Remark 1: Abigail P. Johnson is a Director, the Vice Chairman, the Chief Executive Officer and the President of FMR LLC. Members of the Johnson family, including Abigail P. Johnson, are the predominant owners, directly or through trusts, of Series B voting common shares of FMR LLC, representing 49% of the voting power of FMR LLC. The Johnson family group and all other Series B shareholders have entered into a shareholders' voting agreement under which all Series B voting common shares will be voted in accordance with the majority vote of Series B voting common shares. Accordingly, through their ownership of voting common shares and the execution of the shareholders' voting agreement, members of the Johnson family may be deemed, under the Investment Company Act of 1940, to form a controlling group with respect to FMR LLC. The address of Abigail P. Johnson is c/o FMR LLC, 245 Summer Street, Boston, MA 02110. Remark 2: The general partner of F-Prime Capital Partners Healthcare Fund III LP(f/k/a Beacon Bioventures Fund III Limited Partnership) is F-Prime Capital Partners Healthcare Advisors Fund III LP (f/k/a Beacon Bioventures Advisors Fund III Limited Partnership). F-Prime Capital Partners Healthcare Advisors Fund III LP is solely managed by Impresa Management LLC, its general partner and investment manager. Impresa Management LLC is owned, directly or indirectly, by various shareholders and employees of FMR LLC, including certain members of the Johnson family. Remark 3: The filing of this statement shall not be deemed to be an admission that, for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise, the undersigned are the beneficial owners of any securities reported herein. Marc R. Bryant, Duly authorized under Powers of Attorney, by and on behalf of FMR LLC and its direct and indirect subsidiaries, and Abigail P. Johnson 2016-05-03